



Baxa Ltd
Radius Court
Eastern Road
Bracknell, RG12 2UP

tel: +44 (0) 1344 392902
fax: +44 (0) 1344 392903
info@baxa.co.uk
www.baxa.com

NEWS RELEASE

IMMEDIATE RELEASE

November 24, 2009

Baxa Ltd Expands its Oral/Enteral Product Line with New Female Luer Dispensers

Baxa Ltd expands its specialty product line for non-IV administration with the addition of a complete range of female luer dispensers for oral and enteral medication delivery.

Bracknell, UK – Baxa Ltd, an organisation committed to supplying medical devices that improve the safety of liquid medication delivery, has expanded its range of high-quality ExactaMed™ Oral/Enteral Dispensers with the introduction of devices featuring female luer and female luer lock tips. Baxa dedicated oral/enteral dispensers are designed specifically to prevent wrong-route administrations by means of their unique, non-IV connections.

The complete ExactaMed Oral/Enteral Dispenser product line was developed in accordance with guidelines released by the National Patient Safety Agency (NPSA)¹ in March 2007. The NPSA recommends strong differentiation between oral/enteral dispensers and IV syringes to reduce the risk of wrong-route medication errors. In keeping with the NPSA recommendations, the new female luer dispensers feature a distinctive purple plunger to differentiate them from parenteral syringes, as well as oral/enteral labelling on their protective pouches and barrels. The new tip variants mean the dispensers will connect directly to a patient's feeding tubeset for delivery of medication, for feeds or line flushing.

In addition, all Baxa products have been validated for reuse up to 30 times, making them suitable for safe use in the hospital or the home environment, where policy facilitates. This also ensures cost-effective usage across the Trust.

According to Marketing Manager Stephanie Scott, "Baxa was the first company to produce dispensers designed for oral/enteral use only and is the worldwide market leader today. These new dispensers incorporate the same high-quality features as our existing oral tip dispensers used to deliver medication and nutrition directly into a patient's mouth."

– more –



Baxa Ltd
Radius Court
Eastern Road
Bracknell, RG12 2UP

tel: +44 (0) 1344 392902
fax: +44 (0) 1344 392903
info@baxa.co.uk
www.baxa.com

NEWS RELEASE

Page 2

Female Luer Launch

The Baxa products are available in both female luer tips for direct connection to a patient's tube set, or with oral tips for administration into a patient's mouth. All Baxa dispensers are clearly labelled for oral/enteral use only and have clear barrels with distinctive purple plungers. They are individually wrapped and supplied sterile. The new products are available in 1 and 3 mL sizes with a female luer tip and in 5, 10, 20 and 60 mL sizes with a female luer lock tip.

Established in 1975, Baxa Corporation has a proven track record in the development of highly accurate dispensers for liquid medication, and offers the most comprehensive product range available for safe oral/enteral administration. For more information, visit www.baxa.com.

About Baxa Corporation

Baxa, a customer-focused medical device company, provides innovative, solution-based technologies for medication handling and delivery. Its systems and devices promote the safe and efficient preparation, handling, packaging, and administration of medications. Privately held, Baxa Corporation has subsidiaries and sales offices in Florida, Canada and the United Kingdom; direct representation in Austria, Belgium, Denmark, Finland, France, Germany, Luxembourg, The Netherlands and Switzerland; and distribution partners worldwide. Further information is available at www.baxa.com.

###

Contact:

Stephanie Scott, Marketing, Baxa Ltd:
Tel: +44 (0)1344 392926
Fax: +44 (0)1344 392903
Email: s.scott@baxa.co.uk

Kimberley Gray – Kimberly Gray PR
Tel: 0118 969 4904
Email: kim@kimberleygray.com
www.kimberleygray.com

1. NIH. National Patient Safety Agency. Patient Safety Alert #19: Promoting safer measurement and administration of liquid medicines via oral and other enteral routes. March 2009